Can an oral drug calm psoriatic arthritis? phase 3 trial puts deucravacitinib to the test

NCT ID NCT04908189

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether deucravacitinib, a daily oral drug, can reduce joint swelling, tenderness, and skin symptoms in people with active psoriatic arthritis. The trial enrolls adults who have not taken biologic drugs for their arthritis or who previously received a TNF inhibitor. Participants receive deucravacitinib, a placebo, or apremilast, and researchers compare how many improve by at least 20 percent on a standard arthritis scale after 16 weeks. A longer extension period tracks safety and how well the drug keeps working over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: deucravacitinib, an oral drug that targets a specific immune signaling protein
What this could lead to: If deucravacitinib works, it could offer a new oral option for people with psoriatic arthritis who have not tried biologic drugs or whose previous TNF inhibitor treatment did not help enough.
What could go wrong: The trial may show deucravacitinib does not improve symptoms better than placebo, or that benefits do not last. Like all immune-targeting drugs, it carries risks of infection and other side effects that researchers monitor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

729 people

The number who actually took part.

Started

Jul 2021

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at Screening * Meets the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening * Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at Screening * Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and Day 1 * Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening * Must have completed the week 52 treatment for the optional open-label long-term extension period Exclusion Criteria: * Nonplaque psoriasis at Screening or Day 1 * Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis * History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease) * Active fibromyalgia * Received an approved or investigational biologic therapy for the treatment of PsA or PsO Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriatic arthritis

Contacts and locations

Locations

AOR San Carlo di Potenza-UOC Reumatologia

Potenza, 85100, Italy
Azienda Ospedaliera Universitaria Careggi-Reumatologia

Florence, 50141, Italy
Local Institution

Moscow, 107045, Russia
Local Institution

Novosibirsk, 630099, Russia
Local Institution - 0001

Québec, G1V 3M7, Canada
Local Institution - 0002

Camberwell, Victoria, 3124, Australia
Local Institution - 0003

Botany, New South Wales, 2019, Australia
Local Institution - 0004

Maroochydore, Queensland, 4558, Australia
Local Institution - 0006

Hamilton, Ontario, L8N 1Y2, Canada
Local Institution - 0009

Ostrava, 702 00, Czechia
Local Institution - 0010

Brno, 638 00, Czechia
Local Institution - 0011

Prague, 12850, Czechia
Local Institution - 0012

Madrid, 28041, Spain
Local Institution - 0013

Valencia, 46026, Spain
Local Institution - 0014

Barcelona, 08035, Spain
Local Institution - 0015

Bogotá, 110221, Colombia
Local Institution - 0016

Duncansville, Pennsylvania, 16635, United States
Local Institution - 0017

Geelong, Victoria, 3220, Australia
Local Institution - 0018

Parramatta, New South Wales, 2150, Australia
Local Institution - 0019

Medellín, 50036, Colombia
Local Institution - 0020

Cali, 760035, Colombia
Local Institution - 0022

Chía, 250001, Colombia
Local Institution - 0023

Uherské Hradiště, 686 01, Czechia
Local Institution - 0024

Hódmezővásárhely, 6800, Hungary
Local Institution - 0025

Veszprém, Veszprém City, 8200, Hungary
Local Institution - 0027

Kistarcsa, 2143, Hungary
Local Institution - 0028

Gyula, 5700, Hungary
Local Institution - 0030

Markham, Ontario, L3P 1X3, Canada
Local Institution - 0034

Okemos, Michigan, 48864, United States
Local Institution - 0035

Ostrava, 702 00, Czechia
Local Institution - 0036

Toronto, Ontario, M5T 2S6, Canada
Local Institution - 0038

San Isidro, Buenos Aires, 1642, Argentina
Local Institution - 0039

CABA, Distrito Federal, C1015, Argentina
Local Institution - 0045

Santander, 39008, Spain
Local Institution - 0046

Hamburg, 20095, Germany
Local Institution - 0048

La Plata, Buenos Aires, 1900, Argentina
Local Institution - 0051

Guadalajara, Jalisco, 44650, Mexico
Local Institution - 0052

León, Guanajuato, 37160, Mexico
Local Institution - 0053

Chihuahua City, 31203, Mexico
Local Institution - 0056

Mérida, Yucatán, 97000, Mexico
Local Institution - 0057

Zapopan, Jalisco, 45070, Mexico
Local Institution - 0058

Ghent, 9000, Belgium
Local Institution - 0060

Bradford, BD5 0NA, United Kingdom
Local Institution - 0061

Liège, 4000, Belgium
Local Institution - 0062

London, E11 1NR, United Kingdom
Local Institution - 0064

Hull, HU3 2JZ, United Kingdom
Local Institution - 0065

Shinjuku-ku, Tokyo, 160-8582, Japan
Local Institution - 0066

Debrecen, 4032, Hungary
Local Institution - 0067

Itabashi-ku, Tokyo, 173-0003, Japan
Local Institution - 0070

Mesquite, Texas, 75150, United States
Local Institution - 0072

Barranquilla, Atlántico, 080002, Colombia
Local Institution - 0074

Tübingen, 72076, Germany
Local Institution - 0075

Magdeburg, 39120, Germany
Local Institution - 0077

Liverpool, L9 7AL, United Kingdom
Local Institution - 0078

Brussels, 1200, Belgium
Local Institution - 0079

Gdansk, Pomeranian Voivodeship, 80-546, Poland
Local Institution - 0080

Elblag, 82-300, Poland
Local Institution - 0081

Torun, 87-100, Poland
Local Institution - 0082

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-168, Poland
Local Institution - 0087

Taipei, 11217, Taiwan
Local Institution - 0088

Taichung, 404332, Taiwan
Local Institution - 0089

Taichung, 407, Taiwan
Local Institution - 0090

Taichung, 402, Taiwan
Local Institution - 0091

Taipei, 10002, Taiwan
Local Institution - 0097

Roma, 00168, Italy
Local Institution - 0099

Woodville, South Australia, 5011, Australia
Local Institution - 0101

Cologne, 50937, Germany
Local Institution - 0105

Manchester, M13 9WL, United Kingdom
Local Institution - 0106

Nagoya, Aichi-ken, 4678602, Japan
Local Institution - 0108

New York, New York, 10003, United States
Local Institution - 0109

Hattiesburg, Mississippi, 39402, United States
Local Institution - 0111

Vancouver, British Columbia, V5Z 4E8, Canada
Local Institution - 0112

Wroclaw, 50-088, Poland
Local Institution - 0117

Ürümqi, Xinjiang, 830001, China
Local Institution - 0121

Chuo-ku, Tokyo, 104-8560, Japan
Local Institution - 0122

Minato-ku, Tokyo, 105-8471, Japan
Local Institution - 0123

Kawachi-Nagano, Osaka, 586-8521, Japan
Local Institution - 0125

Changzhou, Jiangsu, 213003, China
Local Institution - 0126

Bengbu, Anhui, 233004, China
Local Institution - 0127

Zhengzhou, Henan, 450000, China
Local Institution - 0129

Wenzhou, Zhejiang, 32500, China
Local Institution - 0131

Nanchang, Jiangxi, 330006, China
Local Institution - 0133

Eagan, Minnesota, 55121, United States
Local Institution - 0134

Kunming, Yunnan, 650032, China
Local Institution - 0135

Guangzhou, Guangdong, 510317, China
Local Institution - 0138

Nanjing, Jiangsu, 210029, China
Local Institution - 0139

Nantong, Jiangsu, 226001, China
Local Institution - 0140

Pingxiang, Jiangxi, 337055, China
Local Institution - 0146

Beijing, Beijing Municipality, 100730, China
Local Institution - 0147

Portland, Oregon, 97239, United States
Local Institution - 0148

Jiujiang, Jiangxi, 332000, China
Local Institution - 0149

Mountain Brook, Alabama, 35223, United States
Local Institution - 0151

Sapporo, Hokkaido, 0608648, Japan
Local Institution - 0152

Beijing, Beijing Municipality, 100083, China
Local Institution - 0153

Guangzhou, Guangdong, 510180, China
Local Institution - 0154

Xi'an, Shan3xi, 710004, China
Local Institution - 0155

Fukuoka, 814-0180, Japan
Local Institution - 0156

Nanchang, Jiangxi, 330006, China
Local Institution - 0157

Hohhot, Neimeng, 010050, China
Local Institution - 0158

Baotou, Neimeng, 014010, China
Local Institution - 0161

Changsha, Hunan, 410011, China
Local Institution - 0163

Wuxi, Jiangsu, 214023, China
Local Institution - 0164

Chengdu, Sichuan, 610072, China
Local Institution - 0166

Osaka, 545-8585, Japan
Local Institution - 0167

Lubbock, Texas, 79424, United States
Local Institution - 0169

Cumberland, Maryland, 21502, United States
Local Institution - 0170

Changsha, Hunan, 410008, China
Local Institution - 0171

San Miguel de Tucumán, Tucumán Province, 4000, Argentina
Local Institution - 0174

Mitaka, Tokyo, 181-8611, Japan
Local Institution - 0175

Milwaukee, Wisconsin, 53217, United States
Local Institution - 0176

Ratingen, North Rhine-Westphalia, 40878, Germany
Local Institution - 0177

Warsaw, Masovian Voivodeship, 02-665, Poland
Local Institution - 0178

Meguro-ku, Tokyo, 1538515, Japan
Local Institution - 0179

Tsu, Mie-ken, 514-8507, Japan
Local Institution - 0180

Cleveland, Ohio, 44106, United States
Local Institution - 0182

Summerville, South Carolina, 29486, United States
Local Institution - 0184

Plano, Texas, 75024, United States
Local Institution - 0185

London, England, SW17 0QT, United Kingdom
Local Institution - 0186

Rochester, New York, 14642, United States
Local Institution - 0187

Seattle, Washington, 98122, United States
Local Institution - 0188

Whittier, California, 90602, United States
Local Institution - 0189

Oklahoma City, Oklahoma, 73116, United States
Local Institution - 0190

Franklin, Wisconsin, 53132, United States
Local Institution - 0192

Skokie, Illinois, 60076, United States
Local Institution - 0195

Baton Rouge, Louisiana, 70836, United States
Local Institution - 0196

Charlotte, North Carolina, 28277, United States
Local Institution - 0197

Budapest, 1062, Hungary
Local Institution - 0198

Mexico City, Mexico City, 14080, Mexico
Local Institution - 0199

Erlangen, 91054, Germany
Local Institution - 0200

Buenos Aires, 1426, Argentina
Local Institution - 0201

Minden, 32429, Germany
Local Institution - 0202

Nagoya, Aichi-ken, 457-8511, Japan
Local Institution - 0203

Hopkinsville, Kentucky, 42240, United States
Local Institution - 0204

Osaka, 550-0006, Japan
Local Institution - 0205

Bunkyō, Tokyo, 113-8519, Japan
Local Institution - 0206

Shenzhen, Guangdong, 518020, China
Local Institution - 0207

Shanghai, Shanghai Municipality, 200052, China
Local Institution - 0212

Sacramento, California, 95815, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.